Cited by 600Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancerPARP inhibition in cancer therapy

The DOI matches its Crossref record; 55 of the 58 references it cites were found in a registry or an index.

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Open access

Perets, Ruth, Wyant, Gregory A., Muto, Katherine W., Bijron, Jonathan G., Poole, Barish B., Chin, Kenneth T., Chen, Jin Yun H., Ohman, Anders W., Stepule, Corey D., Kwak, Soongu, Karst, Alison M., Hirsch, Michelle S., Setlur, Sunita R., Crum, Christopher P., Dinulescu, Daniela M., Drapkin, Ronny·2013·Cancer Cell

DOI 10.1016/j.ccr.2013.10.013PMC PMC3917315

Open this paper in CoChat — free account Open PDF

Abstract

High-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges. Although the traditional model of carcinogenesis has focused on the ovary as a tumor initiation site, recent studies suggest that there may be additional sites of origin outside the ovary, namely the secretory cells of the fallopian tube. Our study demonstrates that high-grade serous tumors can originate in fallopian tubal secretory epithelial cells and also establishes serous tubal intraepithelial carcinoma as the precursor lesion to high-grade serous ovarian and peritoneal carcinomas in animal models targeting the Brca, Tp53, and Pten genes. These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2013.10.013

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 5,237
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C. M., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,114

Flagged first, then by citations

Show all 58 references

3 of the 58 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 600

Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis
Wang, Y., Cai, K. Q., Smith, E. R., Yeasky, T. M., Moore, R. H., Ganjei‐Azar, P., Klein–Szanto, A. J., Godwin, A. K., Hamilton, T. C., & Xu, X. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00202-16 · Cited by 7
Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis
Tseng, S.-H., Park, S. T., Lam, B. K., Tsai, Y.-C., Cheng, M. A., Farmer, E. A., Xing, D., & Hung, C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000480 · Cited by 7
The origins of ovarian cancer
DeWeerdt, S. (2021) · Nature · doi:10.1038/d41586-021-03717-7 · Cited by 7
Fallopian tube precursor lesions of serous ovarian carcinoma require L1CAM for dissemination and metastasisPreprint
Doberstein, K., Spivak, R. Y., Feng, Y., Stückelberger, S., Mills, G. B., Devins, K. M., Schwartz, L. E., Iwanicki, M., Fogel, M., Altevogt, P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/270785 · Cited by 7
Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube
Beddows, I., Djirackor, S., Omran, D. K., Jung, E., Shih, N. N. C., Roy, R., Hechmer, A., Olshen, A. B., Adelmant, G., Tom, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58145-2 · Cited by 7
High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions
Lewis, M. E., Caricato, C., Roberts, H. L., Ganesan, S., Seksaf, N. A., Maniati, E., & Sideris, M. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031617 · Cited by 6
ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer
Webb, J. D., Buensuceso, A. V., Tomas, E. J., Borrelli, M. J., Viola, L. H., Hovey, O. F. J., Valdés, Y. R., Singha, B., Li, S. S.-C., & Shepherd, T. G. (2026) · Oncogene · doi:10.1038/s41388-026-03702-2 · Cited by 7
The ORFIUS complex regulates ORC2 localization at replication origins
Yang, Z., Mogre, S., He, R., Berdan, E. L., Sui, S. J. H., & Hill, S. J. (2024) · NAR Cancer · doi:10.1093/narcan/zcae003 · Cited by 6
HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cells
He, C., Lv, X., Liu, J., Ruan, J., Chen, P., Huang, C., Angeletti, P. C., Hua, G., Moness, M. L., Shi, D., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00233-3 · Cited by 6
Transplantation Into the Mouse Ovarian Fat Pad
Flesken‐Nikitin, A., Harlan, B. A., & Nikitin, A. Y. (2016) · Journal of Visualized Experiments · doi:10.3791/54444 · Cited by 6
The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
O’Connell, C., VandenHeuvel, S. N., Kamat, A. A., Raghavan, S. A., & Godin, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179981 · Cited by 6
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
Weir, A. L., Kang, E.-Y., Meagher, N. S., Nelson, G. S., Ghatage, P., Lee, C., Riggan, M. J., Gentry‐Maharaj, A., Ryan, A., Singh, N., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02014-y · Cited by 6
Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma
Chang, Y., Chu, T., & Ding, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213843 · Cited by 6
Genetically engineered mouse models for hereditary cancer syndromes
Biswas, K., Mohammed, A., Sharan, S. K., & Shoemaker, R. H. (2023) · Cancer Science · doi:10.1111/cas.15737 · Cited by 5
Biomarkers for Systemic Therapy in Ovarian Cancer
Pénzváltó, Z., Surowiak, P., & Győrffy, B. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140310120107 · Cited by 6
The fallopian tube as the origin of non‐uterine pelvic high‐grade serous carcinoma
Aggarwal, I., Lim, Y. H., & Lim, T. Y. K. (2016) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12258 · Cited by 6
Ovarian Epithelial Carcinogenesis
Zhang, J., Silva, E. G., Sood, A. K., & Liu, J. (2019) · Springer eBooks · doi:10.1007/978-981-13-3019-3_4 · Cited by 6
BRCA gene testing in women with high-grade serous ovarian carcinoma
Kansu, B., Gardner, J. M., Price-Tate, R., Murch, O., & Murray, A. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1820466 · Cited by 6
Lineage tracing of mutant granulosa cells reveals in vivo protective mechanisms that prevent granulosa cell tumorigenesis
Niu, S., Cheng, K., Jia, L., Liang, J., Mu, L., Wang, Y., Yang, X., Chen, Y., Zhang, Y., Wang, C., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01132-1 · Cited by 6
Oncogenes in high grade serous adenocarcinoma of the ovary
Manasa, P., Sidhanth, C., Krishnapriya, S., Vasudevan, S., & Ganesan, T. S. (2020) · Genes & Cancer · doi:10.18632/genesandcancer.206 · Cited by 6
Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer
Rayamajhi, S., Sipes, J., Ngala, B., Mitra, A., Li, M., Trinidad, C. V., Cui, W., Rahman, M. M., Ahmmed, F., Bantis, L. E., et al. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101508 · Cited by 6
Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells
Nathan, N., Paparoditis, P., Sarusi-Portuguez, A., Stoler‐Barak, L., Horn, H. M., Milo, I., Mazor, R. D., Levy‐Barda, A., Yanichkin, N., Borcherding, N., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.04.017 · Cited by 5
Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses
Cavarzerani, E., Caligiuri, I., Bartoletti, M., Corona, G., Perin, T., Palumbo, A., Ditto, A., Occhiali, T., Canzonieri, V., & Rizzolio, F. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.009 · Cited by 6
Proteomic Analysis of Pre-Invasive Serous Lesions of the Endometrium and Fallopian Tube Reveals Their Metastatic Potential
Acland, M., Arentz, G., Mussared, M., Whitehead, F., Hoffmann, P., Klingler‐Hoffmann, M., & Oehler, M. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.523989 · Cited by 5
Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design
Nag, J. K., Grisaru‐Granovsky, S., Armon, S., Rudina, T., Appasamy, P., & Bar‐Shavit, R. (2024) · Biomedicines · doi:10.3390/biomedicines12010246 · Cited by 5
Phenome‐wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers
Mulugeta, A., Lumsden, A. L., Madakkatel, I., Stacey, D., Lee, S., Maenpaa, J. U., Oehler, M. K., & Hyppönen, E. (2024) · Cancer Medicine · doi:10.1002/cam4.7051 · Cited by 4
Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma
Main, H. G., Macias, V., Kajdacsy‐Balla, A., & Barbolina, M. V. (2015) · Biomolecules · doi:10.3390/biom5043438 · Cited by 5
Models for measuring metabolic chemical changes in the metastasis of high grade serous ovarian cancer: fallopian tube, ovary, and omentum
Lusk, H. J., Burdette, J. E., & Sanchez, L. M. (2021) · Molecular Omics · doi:10.1039/d1mo00074h · Cited by 5
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression
Drakes, M. L., & Stiff, P. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73359-9_3 · Cited by 5
Innate Immune Program in Formation of Tumor-Initiating Cells from Cells-of-Origin of Breast, Prostate, and Ovarian Cancers
Han, S., Chen, X., & Li, Z. (2023) · Cancers · doi:10.3390/cancers15030757 · Cited by 6
Dichotomous ovarian cancer-initiating potential of Pax8+ cells revealed by a mouse genetic mosaic model
Zeng, J., Álvarez-Yela, A. C., Casarez, E. V., Jiang, Y., Wang, L., Kelly, B. E., Jenkins, T. M., Ke, E., Atkins, K. A., Janes, K. A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106742 · Cited by 5
Profiling extracellular vesicles in circulation enables the early detection of ovarian cancerPreprint
Jo, A., Green, A., Medina, J. E., Iyer, S., Öhman, A., McCarthy, E. T., Reinhardt, F., Gerton, T. J., Demehin, D., Mishra, R. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.19.524549 · Cited by 5
Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma
Paris, E. A., Bahr, J. M., Basu, S., & Barua, A. (2023) · Cancers · doi:10.3390/cancers15030661 · Cited by 5
Fallopian Tube-Derived High-Grade Serous Cancers Influence Ovarian Production of Norepinephrine and Generate Specific Metabolomic Signatures
Bergsten, T. M., Lusk, H. J., Haughan, M. A., Guerrero, J. A., Levy, S. E., Lantvit, D. D., Sanchez, L. M., & Burdette, J. E. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00238 · Cited by 4
Ovulation sources ROS to confer mutagenic activities on the TP53 gene in the fallopian tube epithelium
Subramani, K., Huang, H.-S., Chen, P.-C., Ding, D.-C., & Chu, T.-Y. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101085 · Cited by 5
A Quest for Better Mouse Models of Breast and Ovarian Cancers
Harlan, B. A., & Nikitin, A. Y. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.09.017 · Cited by 4
Oncogenic Events Dictate the Types and Locations of Gynecological Malignancies Originating from Krt8+ Mesothelial and Müllerian-Derived Epithelial Cells
Park, E., Xiang, D., Xie, Y., Bronson, R. T., & Li, Z. (2022) · Cancers · doi:10.3390/cancers14030841 · Cited by 4
Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk‐reducing salpingo‐oophorectomies
Veskimäe, K., Staff, S. M., Tabaro, F., Nykter, M., Isola, J. J., & Maenpaa, J. U. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22241 · Cited by 4
Diseases of the Fallopian Tube and Paratubal Region
VANG, R. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46334-6_11 · Cited by 4
3D multi-omic mapping of whole nondiseased human fallopian tubes at cellular resolution reveals a large incidence of ovarian cancer precursorsPreprint
Forjaz, A., Queiroga, V., Li, Y., Hernandez, A., Crawford, A. J., Qin, X., Zhong, M., Tsapatsis, M., Joshi, S., Kramer, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.21.677628 · Cited by 4
Immunocompetent C57BL/6 syngeneic mouse ovarian cancer models with defined genetic alterations
Agadjanian, H., Karlan, B. Y., Walsh, C., & Oršulić, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-18960-5 · Cited by 3
Haematopoietic innate interleukin 17A production drives immunopathology in female mouse genital Chlamydia muridarum infection
Armitage, C. W., Bryan, E. R., Trim, L. K., Palframan, E., Wager, L. J., Beagley, K. W., & Carey, A. J. (2024) · Scandinavian Journal of Immunology · doi:10.1111/sji.13359 · Cited by 3
The Identification of a Key Regulator of Mitochondrial Metabolism, the LRPPRC Protein, as a Novel Therapeutic Target in SDHA-Overexpressing Ovarian Tumors
Szulta, A., Wang, L., Hasan, A., Kinter, M. T., Pranay, A., Zhu, J., Humphries, K. M., Loveland, B. L., Griffin, T. M., & Bieniasz, M. (2025) · Cancers · doi:10.3390/cancers17121942 · Cited by 3
Pathogenesis of peritoneal high‐grade serous carcinoma after risk‐reducing surgery: a systematic review
Gootzen, T. A., Bouwmeester, A. B., de Hullu, J. A., Piek, J. M. J., van der Laak, J. A. W. M., Simons, M., & Steenbeek, M. P. (2025) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70037 · Cited by 3
Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice
Upton, D. H., Walters, K. A., Allavena, R., Jimenez, M., Desai, R., Handelsman, D. J., & Allan, C. M. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0272-3 · Cited by 3
A Protocol for the Acquisition of Comprehensive Proteomics Data from Single Cases Using Formalin-Fixed Paraffin Embedded Sections
Acland, M., Mittal, P., Arentz, G., Whitehead, F., Hoffmann, P., Klingler‐Hoffmann, M., & Oehler, M. K. (2022) · Methods and Protocols · doi:10.3390/mps5040057 · Cited by 3
Generation of Oviductal Glycoprotein 1 Cre Mouse Model for the Study of Secretory Epithelial Cells of the Oviduct
McGlade, E. A., Mao, J., Stephens, K. K., Kelleher, A. M., Maddison, L. A., Bernhardt, M. L., DeMayo, F. J., Lydon, J. P., & Winuthayanon, W. (2024) · Endocrinology · doi:10.1210/endocr/bqae070 · Cited by 3
Serous tubal intraepithelial carcinoma—looking into the earliest events of ovarian cancer development
Shih, I., Wang, Y., & VANG, R. S. (2025) · Academia oncology. · doi:10.20935/acadonco7620 · Cited by 3
Adult Stem Cell Niches — Stem Cells in the Female Reproductive System
Kessler, M., Zietlow, R., & Meyer, T. F. (2014) · InTech eBooks · doi:10.5772/58842 · Cited by 4
Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary (Review)
Kobayashi, H., Kawahara, N., Ogawa, K., Yamada, Y., Iwai, K., Niiro, E., & Morioka, S. (2018) · Biomedical Reports · doi:10.3892/br.2018.1114 · Cited by 3
Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Stott, W., Gentry‐Maharaj, A., Ryan, A., Amso, N. N., Seif, M. W., Jones, C., Jacobs, I. J., Parmar, M., Menon, U., Campbell, S. C., et al. (2018) · F1000Research · doi:10.12688/f1000research.15663.1 · Cited by 3
Meeting report from the 2018 12th Biennial Ovarian Cancer Research Symposium detection and prevention of ovarian cancer
Xian, W., & George, S. H. L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000454 · Cited by 3
Mouse models for cancer research – current state and the perspective
Gercakova, K., Poturnajova, M., Tyčiaková, S., Režuchová, I., & Matúšková, M. (2024) · Neoplasma · doi:10.4149/neo_2024_240328n140 · Cited by 3
Novel Cancer Prevention Strategies in Individuals With Hereditary Cancer Syndromes: Focus on BRCA1, BRCA2, and Lynch Syndrome
Bowen, C. M., Demarest, K., Vilar, E., & Shah, P. D. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433576 · Cited by 3
Bioinformatic and experimental data pertaining to the role of the NLRP3 inflammasome in ovarian cancer
Ashmore, A. A., Balasubramanian, B., Phillips, A., Asher, V., Bali, A., Ordóñez‐Morán, P., & Khan, R. N. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05988-9 · Cited by 2
Uncloaking the Fimbria Ovarica
Seidman, J. D., Stone, R. L., Moragianni, V. A., Krishnan, J., & VANG, R. S. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002414 · Cited by 2
Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist’s perspective
Alves‐Vale, C., Galvão, B., Silvestre, A. R., Pereira, J. S., Bei, L., Fernandes, J. P., Borralho, P., Carmo‐Fonseca, M., & Custódio, N. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01766-4 · Cited by 2
Cell state dynamics during early stages of serous endometrial carcinoma
Flesken‐Nikitin, A., Pirtz, M. G., Ashe, C. S., Ellenson, L. H., Yemelyanova, A. V., Cosgrove, B. D., & Nikitin, A. Y. (2025) · The Journal of Pathology · doi:10.1002/path.6470 · Cited by 4
Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Hallberg, D. L., Eastman, A. C., Koul, S., Bruhm, D. C., Papp, E., Davenport, S., Adleff, V., Ferreira, L., Niknafs, N., Medina, J. E., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0147 · Cited by 2
Gynecologic Manifestations of Hereditary Syndromes: Clinical and Imaging Spectrum
Maheshwari, E., Wahab, S. A., Wasnik, A. P., Maturen, K. E., Mai, P. L., Sholosh, B., Shinagare, A. B., Sukumvanich, P., & Venkatesan, A. M. (2025) · Radiographics · doi:10.1148/rg.240223 · Cited by 2
From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review
Georgy, D., Sedeek, H. N., Abaza, N. E., Eldeeb, S. E. K., Khamis, S. M., Elgamil, M. R., & Magar, R. W. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102564 · Cited by 3
Epithelial Ovarian Cancer Prevention
Chambers, S. K., & Hess, L. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_20 · Cited by 1
High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer
Jacob, F., Marchetti, R. L., Kind, A. B., Russell, K., Schoetzau, A., & Heinzelmann-Schwarz, V. A. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12811 · Cited by 2
Assessment of Fallopian Tube Epithelium Features Derived from Induced Pluripotent Stem Cells of Both Fallopian Tube and Skin Origins
Chang, Y., Wu, K., Wang, K., & Ding, D. (2023) · Cells · doi:10.3390/cells12222635 · Cited by 2
EM-transcriptomic signature predicts drug response in advanced stages of high-grade serous ovarian carcinoma based on ascites-derived primary cultures
Constantinescu, D., Sorop, A., Ghionescu, A.-V., Lixandru, D., Herlea, V., Bacalbașa, N., & Dima, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1363142 · Cited by 2
Synergistic modulation of p53-HMGB1 complex and its binding to DNA: The role of nanotechnology in overcoming cancer drug resistance; A literature review and in-silico analysis
Heidari, Z., BabaeiGhazvini, J., Hosseinpour-Soleimani, F., Salmasi, Z., Mortazavi, M., Tajbakhsh, A., & Irajie, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147378 · Cited by 2
Origins of Epithelial Ovarian Cancer
Dubeau, L., & Teixeira, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00001-x · Cited by 1
Ovarian Cancer and the Environment: Rodent Models
Vanderhyden, B. C., & Dorward, A. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.10927-4 · Cited by 2
Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?
Samimi, G., & Minasian, L. M. (2017) · Cancer · doi:10.1002/cncr.30525 · Cited by 2
Extracellular Vesicles and Ovarian Cancer
Aviles, D., Warshal, D. P., Krill, L. S., & Ostrovsky, O. (2021) · Physiology · doi:10.5772/intechopen.101412 · Cited by 2
Epithelial Tumors of the Ovary
Seidman, J. D., Ronnett, B. M., Shih, I., Cho, K. R., & Kurman, R. J. (2018) · Springer eBooks · doi:10.1007/978-1-4614-3165-7_14-2 · Cited by 2
Vaginal bacteria elicit acute inflammatory response in fallopian tube organoids: a model for pelvic inflammatory diseasePreprint
Yu, B., Nguyen, E. B., McCartney, S. A., Strenk, S. M., Valint, D. J., Liu, C., Haggerty, C. L., & Fredricks, D. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.06.527402 · Cited by 2
Deep spatial proteomics of ovarian cancer precursor lesions delineates early disease changes and cell-of-origin signaturesPreprint
Makhmut, A., Dragomir, M. P., Fritzsche, S., Möbs, M., Schmitt, W., TAUBE, E. T., & Coscia, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.19.643504 · Cited by 2
Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancerPreprint
Metousis, A., Kenny, H. A., Shimizu, A., Schweizer, L., Ben‐Moshe, S., Bilecz, A. J., Krishnan, R., Zhang, J., Alcazar, I. N., Kelliher, L., et al. (2025) · medRxiv · doi:10.1101/2025.08.25.25333715 · Cited by 2
Models of High-Grade Serous Ovarian CarcinomaPreprint
Pundel, O. J., & Neel, B. G. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041949 · Cited by 2
Molecular Basis of BRCA1 and BRCA2: Homologous Recombination Deficiency and Tissue-Specific Carcinogenesis
Ohta, T., & Wu, W. (2021) · Springer eBooks · doi:10.1007/978-981-16-4521-1_2 · Cited by 1
Cancer risk in polycystic ovary syndrome patients: Common treatments and future perspectives
Shahrin, A., Mele, M. A., & Islam, M. Z. (2023) · Journal of Multidisciplinary Sciences · doi:10.33888/jms.2023.515 · Cited by 1
Ovarian Cancer and the Environment: Rodent Models
Vanderhyden, B. C., & Dorward, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00099-1 · Cited by 1
Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer
Zhang, L., Fang, Y., Uygun, I., Li, D., Strange, M., Zaidi, S. K., Wang, W., Knight, J. C., Radolec, M., Elishaev, E., et al. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052177 · Cited by 1
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Tseng, C.-C., Ku, M.-H., Wu, W.-M., Mendez, A., Christner, T., Wu, Y., Huang, W.-L., Chen, Y.-H., Huang, C., Barefoot, J., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01571-2 · Cited by 1
Development of Mouse-Derived Organoid Lines from Fallopian Tube Epithelial Cells for High Grade Serous Ovarian Carcinoma Modeling
González, E. M. H., Hou, J., & Pundel, O. J. (2025) · Journal of Visualized Experiments · doi:10.3791/68753 · Cited by 2
Integrative multi-omic analysis reveals a PAX8-driven gene network linking tumor stemness to therapy response in ovarian cancer
Santos-Pereira, J. M., Carnero, A., & Muñoz-Galván, S. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf113 · Cited by 1
Mutant p53 disrupts antioxidant defense in fallopian tube epithelium via GSTAs suppression: A pathway to serous tubal carcinogenesis
Burnett, D. B., Hilaire, S. S., Dodds, L. V., Nelson, O. L., Ravix, J., Sowamber, R., Sealy, A. J., Paudel, I., Morales, O., Xu, X., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.11.027 · Cited by 1
High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease
Szabova, L., Lu, L., Gordon, M. B., Johnson, K., Guerin, T. M., Bassel, L., Householder, D. B., Edouard, M., Ries, A., Kozlov, S. V., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114238 · Cited by 1
Genomics of ovarian cancers and the potential of precision medicine
Jarratt, A., Polidano, J., Scott, C. L., & Barker, H. E. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396651 · Cited by 1
Insights from three decades of BRCA1/2 modeling in mice
Darnold, J.-S., & Jonkers, J. (2026) · Nature Genetics · doi:10.1038/s41588-025-02448-z · Cited by 1
BNC2 in Development and Disease: Regulatory Mechanisms and Translational Implications
Wei, X., Du, Y., Liu, X., & Zhang, L. E. (2026) · Molecules · doi:10.3390/molecules31122088 · Cited by 1
Efficient analyses of DNA double-strand breaks and the cell cycle in the secretory epithelial cells of fallopian tube fimbriae
Huang, H.-S., Chu, S., & Chu, T. (2015) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2015.05.004 · Cited by 1
Orientation of Preclinical Research in Ovarian Cancer
Baert, T., Garg, A. D., Agostinis, P., Vergote, I. B., & Coosemans, A. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001053 · Cited by 1
Examination of expression patterns of WNT signaling in the human fallopian tubes
Özyurt, N., Bostancıeri, N., Kahraman, D. T., Ovayolu, A., & Bozdağ, Z. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100821 · Cited by 1
Rare germline genetic variation in PAX8 transcription factor binding sites and susceptibility to epithelial ovarian cancer
Ezquina, S., Jones, M., Dicks, E., de Vries, A., Peng, P.-C., Lawrenson, K., Corona, R. I., Tyrer, J. P., Hazelett, D. J., Brenton, J. D., et al. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae301 · Cited by 1
Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors
Upton, D. H., Fuller, E. S., Colvin, E. K., Walters, K. A., Jimenez, M., Desai, R., Handelsman, D. J., Howell, V. M., & Allan, C. M. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0222-5 · Cited by 1
Precursors of High-Grade Serous Carcinoma
Shaw, P. A., Clarke, B. A., & George, S. H. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-22509-8_1 · Cited by 1
Preclinical models in ovarian cancer
Bolland, D. E., & McLean, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00002-7 · Cited by 1
Ovarian Cancer Animal Models for Preclinical Studies and Development of Ovarian Cancer Drugs
Sandhiutami, N. M. D., Wuyung, P. E., Arozal, W., Louisa, M., & Rahmat, D. (2019) · JURNAL ILMU KEFARMASIAN INDONESIA · doi:10.35814/jifi.v17i2.734 · Cited by 1
Experimental models in the study of pathogenesis and the development of treatments for ovarian cancer (systematic review)
Zhukova, G. V., Verenikina, E. V., Protasova, T. P., Yakubova, D. Y., & Volkova, А. V. (2021) · Voprosy Onkologii · doi:10.37469/0507-3758-2021-67-4-463-473 · Cited by 1
Microdissection and Dissociation of the Murine Oviduct: Individual Segment Identification and Single Cell Isolation
Radecki, K. C., Lorenson, M. Y., Carter, D. G., & Walker, A. M. (2021) · Journal of Visualized Experiments · doi:10.3791/63168 · Cited by 1
Ex Vivo Ovarian Culture to Model the Initial Metastasis in Ovarian Cancer
Dean, M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1956-8_13 · Cited by 1
Animal Models of Gynecological Cancers
Venkata, P. P., Medina, D., Nirzhor, S. S. R., Sittadjody, S., Kumaran, R., Ramachandran, I., & Subbarayalu, P. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_18-1 · Cited by 1
The Role of Steroid Hormones, GREB1, and Reproductive Status in Ovarian Cancer Progression
Hodgkinson, K. M. (2016) · uO Research (University of Ottawa) · doi:10.20381/ruor-5777 · Cited by 1

Authors: Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., Karst, A. M., Hirsch, M. S., Setlur, S. R., Crum, C. P., Dinulescu, D. M., & Drapkin, R.
Affiliations: Harvard University (US)
Brigham and Women's Hospital (US)
Corresponding author: Dinulescu, Daniela M.
Drapkin, Ronny
ORCID: Perets, Ruth
Wyant, Gregory A.
Hirsch, Michelle S.
Setlur, Sunita R.
Crum, Christopher P.
Dinulescu, Daniela M.
Drapkin, Ronny
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2013-12
Volume: 24
Issue: 6
Pages: 751-765
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2013.10.013
PMC: PMC3917315
OpenAlex: W2013107316
Cited by: 596
References: 58
Citations by year: 2026: 23 · 2025: 49 · 2024: 35 · 2023: 47 · 2022: 47 · 2021: 46 · 2020: 85 · 2019: 44 · 2018: 42 · 2017: 44 · 2016: 51 · 2015: 49 · 2014: 32
FWCI: 52.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 373 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Wellcome Trust
National Institutes of Health
National Cancer Institute (R21CA156021, U01CA152990, P50CA105009)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: high-grade serous ovarian cancer, serous tubal intraepithelial carcinoma, cancer of unknown primary, BRCA1, BRCA2, TP53, PTEN, peritoneal cancer, precursor lesions, cancer prevention, early detection
MeSH terms: PAX8 Transcription Factor, Animals, Cell Transformation, Neoplastic, Epithelium, Fallopian Tube Neoplasms, Female, Mice, Inbred C57BL, Ovarian Neoplasms, Precancerous Conditions, Genes, p53, Cystadenocarcinoma, Serous, Genes, BRCA1, Integrases, Genes, BRCA2, PTEN Phosphohydrolase, Mice, Paired Box Transcription Factors, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks